The latest announcement is out from PharmaTher Holdings Ltd ( ($TSE:PHRM) ). PharmaTher Holdings Ltd. has received FDA approval for its ketamine ...

PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates ...

PharmaTher Holdings Ltd. (the 'Company” or 'PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, announced today ...

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company ...

The FDA has approved Ketarx, a ketamine-based drug developed by drugmaker PharmaTher, for use in pain management. The medication is now cleared by the FDA for clinical use in perioperative settings, ...

PharmaTher Holdings Ltd ( ($TSE:PHRM) ) just unveiled an update. PharmaTher Holdings Ltd. has received FDA approval for its ketamine product, ...

The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical ...

"PharmaTher is committed to revolutionizing patient care through ketamine. With KetaVault™, PharmaTher isn't just sharing data; we're igniting a new era of collaborative ketamine innovation.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the research and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health ...

--PharmaTher Holdings Ltd., a specialty psychedelic pharmaceutical company, today announced it submitted an Investigational New Drug application with the U.S. Food and Drug Administration for the ...

PharmaTher Holdings Ltd. PHRRF PHRM is focused on the research, development and commercialization of specialty ketamine prescription-based products including KETAPATCH, a ketamine microneedle ...

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to ...